Compendium of Cancer Genome Aberrations

STBT5:Volunteer Assignments and Opportunities: Difference between revisions

[checked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(23 intermediate revisions by 3 users not shown)
Line 229: Line 229:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]]
|[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]]
Line 251: Line 251:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/16/2025
|
|Katie Schieffer
|
|10/16/2025
|
|No genetic association
|-
|-
|[[STBT5:Elastofibroma|Elastofibroma]]
|[[STBT5:Elastofibroma|Elastofibroma]]
Line 297: Line 297:
|Katie Schieffer
|Katie Schieffer
|9/22/2025
|9/22/2025
|
|No genetic association
|-
|-
|[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]]
|[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]]
Line 315: Line 315:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/16/2025
|
|Katie Schieffer
|
|10/16/2025
|
|No genetic association
|-
|-
|[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]]
|[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]]
Line 381: Line 381:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/21/2025
|
|Katie Schieffer
|
|10/21/2025
|
|
|-
|-
Line 423: Line 423:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|No genetic association
|-
|-
|[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]]
|[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]]
Line 453: Line 453:
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]]
|[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]]
|Disease
|Disease
|Kate Schieffer
|Kati
e Schieffer
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]]
|[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]]
Line 517: Line 518:
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]]
|Disease
|Disease
|Yiting Li (trainee), Shashirekha Shetty (mentor)
|Yiting Li (trainee);
Shashirekha Shetty (mentor)
|9/24/2025
|9/24/2025
|12/24/2025
|12/24/2025
|PENDING
|COMPLETE
|
|12/18/2025
|
|Katie Schieffer
|
|12/18/2025
|
|
|-
|-
Line 542: Line 544:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]]
|[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]]
Line 561: Line 563:
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]]
|[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]]
|Disease
|Disease
|Mokhtar Abdelhammed, MD (trainee);
Katie Schieffer (mentor)
|3/1/2026
|6/30/2026
|PENDING
|
|
|
|
|
|
|
|
|
|-
|
|
|
|-
|[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]]
|[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]]
|Disease
|Disease
Line 661: Line 664:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|No genetic association
|-
|-
|[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]]
|[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]]
Line 672: Line 675:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Synovial_haemangioma|Synovial haemangioma]]
|[[STBT5:Synovial_haemangioma|Synovial haemangioma]]
Line 683: Line 686:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/10/2025
|
|Katie Schieffer
|
|11/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Intramuscular_angioma|Intramuscular angioma]]
|[[STBT5:Intramuscular_angioma|Intramuscular angioma]]
Line 694: Line 697:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]]
|[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]]
Line 716: Line 719:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/10/2025
|
|Katie Schieffer
|
|12/10/2025
|
|No genetic association
|-
|-
|[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]]
|[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]]
Line 780: Line 783:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]]
|[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]]
Line 791: Line 794:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|Minimal genetic content added
|-
|-
|[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]]
|[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]]
Line 910: Line 913:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]]
|[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]]
Line 1,095: Line 1,098:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|No genetic association
|-
|-
|-
|-
Line 1,115: Line 1,118:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/11/2025
|
|Katie Schieffer
|
|12/11/2025
|
|No genetic association
|-
|-
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]]
|[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]]
Line 1,130: Line 1,133:
|
|
|
|
|
|Consider linking to CNS tumor book
|-
|-
|[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]]
|[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]]
Line 1,190: Line 1,193:
|Disease
|Disease
|Katie Schieffer
|Katie Schieffer
|921/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]]
|[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]]
Line 1,264: Line 1,267:
|[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]]
|[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]]
|Disease
|Disease
|Mokhtar Abdelhammed, MD
|Mokhtar Abdelhammed, MD (trainee);
Katie Schieffer (mentor)
|9/11/2025
|9/11/2025
|12/11/2025
|12/11/2025
|PENDING
|COMPLETE
|
|12/29/2026
|Katie Schieffer
|Katie Schieffer
|
|1/7/2026
|
|
|-
|-
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]]
|[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]]
|Disease
|Disease
|
|Mokhtar Abdelhammed, MD (trainee);
|
Katie Schieffer (mentor)
|
|3/1/2026
|
|6/30/2026
|PENDING
|
|
|
|
Line 1,330: Line 1,335:
|[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]]
|[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]]
|Disease
|Disease
|
|Maxine Sutcliffe, PhD
|
|10/13/2025
|
|12/31/2025
|
|COMPLETE
|
|12/24/2025
|
|Katie Schieffer
|
|12/24/2025
|
|
|-
|-
Line 1,372: Line 1,377:
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]]
|[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]]
|Disease
|Disease
|
|Maxine Sutcliffe, PhD
|
|1/12/2026
|
|4/12/2026
|
|PENDING
|
|
|
|
Line 1,448: Line 1,453:
|[[STBT5:Ewing_sarcoma|Ewing sarcoma]]
|[[STBT5:Ewing_sarcoma|Ewing sarcoma]]
|Disease
|Disease
|Sadeem Qdaisat
|Sadeem Qdaisat (trainee); Eric McGinnis (mentor)
|10/1/23
|10/1/2023
|12/9/2025
|12/9/2025
|PENDING
|PENDING
|
|
|Working with Eric McGinnis
|Katie Schieffer
|
|
|
|2021 template added
|-
|-
|[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]]
|[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]]
Line 1,525: Line 1,530:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|12/12/2025
|
|Katie Schieffer
|
|12/12/2025
|
|No genetic association
|-
|-
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]]
|[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]]
Line 1,536: Line 1,541:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
<br />
|12/8/2025
|
|Katie Schieffer
|
|12/8/2025
|
|
|
|-
|-
Line 1,581: Line 1,585:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|
|-
|-
Line 1,624: Line 1,628:
|Katie Schieffer
|Katie Schieffer
|9/21/2025
|9/21/2025
|12/21/2025
|12/31/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|
|-
|-
Line 1,772: Line 1,776:
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|[[STBT5:Osteosarcoma|Osteosarcoma]]
|Disease
|Disease
|Fang Fang (trainee); Katie Schieffer (mentor)
|11/19/2025
|2/15/2026
|PENDING
|
|
|
|Katie Schieffer
|
|
|
|
|
|
|
|
Line 1,852: Line 1,856:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association
|-
|-
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]]
|[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]]
Line 1,960: Line 1,964:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association, early genetic studies referenced
|-
|-
|[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]]
|[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]]
Line 1,982: Line 1,986:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|11/14/2025
|
|Katie Schieffer
|
|11/14/2025
|
|No genetic association
|-
|-
|[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]]
|[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]]
Line 1,993: Line 1,997:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/22/2025
|
|Katie Schieffer
|
|10/22/2025
|
|
|-
|-
Line 2,024: Line 2,028:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/21/2025
|
|Katie Schieffer
|
|10/21/2025
|
|
|-
|-
Line 2,035: Line 2,039:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/21/2025
|
|Katie Schieffer
|
|10/21/2025
|
|
|-
|-
Line 2,061: Line 2,065:
|
|
|
|
|
|Refer to lipoma and hibernoma pages in STBT book
|-
|-
|[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]]
|[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]]
Line 2,072: Line 2,076:
|
|
|
|
|
|Refer to leiomyosarcoma page in STBT book
|-
|-
|[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]]
|[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]]
Line 2,090: Line 2,094:
|9/21/2025
|9/21/2025
|12/21/2025
|12/21/2025
|PENDING
|COMPLETE
|
|10/21/2025
|
|Katie Schieffer
|
|10/21/2025
|
|
|-
|-
Line 2,105: Line 2,109:
|
|
|
|
|
|Refer to plasmacytoma page in heme book
|-
|-
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]]
|[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]]
Line 2,116: Line 2,120:
|
|
|
|
|
|Refer to heme book
|-
|-
|-
|-
Line 2,136: Line 2,140:
|
|
|
|
|
|Refer to heme book
|-
|-
|[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]]
|[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]]
Line 2,147: Line 2,151:
|
|
|
|
|
|Refer to heme book
|-
|-
|[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
|[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]]
Line 2,158: Line 2,162:
|
|
|
|
|
|Refer to heme book
|-
|-
|
|
Retrieved from "https://test.ccga.io/index.php/STBT5:Volunteer_Assignments_and_Opportunities"